(Press-News.org) Jerusalem, Sept. 6, 2012 – A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.
The researcher is Saul Yedgar, who is the Walter and Greta Stiel Professor of Heart Studies at the Institute for Medical Research Israel-Canada at the Hebrew University Faculty of Medicine.
Inflammatory/allergic diseases affect billions of people worldwide, and treatments for these conditions are a major focus of the pharmaceutical industry. The most common drugs currently used to treat these numerous diseases are steroids, which are potent but are associated with severe side effects. These include metabolic changes (weight gain, increased blood pressure, diabetes), organ-specific effects (glaucoma, cataracts, bone fragility), and even psychotrophic side effects (depression, psychosis).
For decades, alternatives, such as biological NSAIDs (non-steroidal alternative anti-inflammatory drugs) have been the focus of the pharmaceutical industry. The resulting drugs have been commercially successful, but have not produced genuine alternatives to steroids due to their limitations. Synthetic NSAIDs are less potent and have their own serious side effects, including cardiovascular disorders, stomach bleeding and respiratory disorders. The biological drugs are costly and, must be injected and have rare but very severe side effects.
Inflammatory/allergic diseases present different symptoms affecting different organs, such as skin inflammations (dermatitis, psoriasis); airway injury and allergy (asthma, cystic fibrosis, allergic rhinitis); osteoarthritis and rheumatoid arthritis; intestinal inflammation (ulcerative colitis, Crohn's disease); central nervous system inflammation (multiple sclerosis), as well as atherosclerosis and cancer metastasis.
What they have in common is that all of them share biochemical mechanisms. A key one among them is the action of an enzyme family (PLA2) that initiates the production of a cascade of pro-inflammatory mediators involved in the induction and propagation of the diverse inflammatory diseases.
In Prof. Yedgar's lab at the Hebrew University, he and his associates have designed and constructed an entirely novel synthetic generation of drugs that control the PLA activity and the subsequent cascade of pro-inflammatory mediators, thereby providing multi-functional, anti-inflammatory drugs (MFAIDs).
MFAIDs have shown excellent safety and were found efficient in treating diverse inflammatory/allergic conditions in animal models, using different ways of administration – oral, rectal, intravenous, inhaled and injected. These conditions included sepsis, inflammatory bowel diseases, asthma and central nervous system inflammation.
In particular, in two clinical studies MFAIDs have been shown to be safe and efficient in treating contact dermatitis, when incorporated into skin cream, and allergic rhinitis, when administered as a nasal spray.
This platform technology has been exclusively licensed from the Hebrew University through the university's Yissum Technology Transfer Company to Morria Biopharmaceuticals PLC (a British company), which is currently developing these drugs to treat inflammatory diseases of the airways (hay-fever, cystic fibrosis), the skin (eczema), the eye (conjunctivitis) and the gut (colitis, Crohn's disease).
For his groundbreaking work, Prof. Yedgar was one of the winners of this year's Kaye Innovation Awards at the Hebrew University. The Kaye Awards have been given annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society. The awards were presented this year during the annual meeting of the Hebrew University Board of Governors.
INFORMATION:
Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
2012-09-06
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Earlier treatment for young patients with chronic hepatitis B more effective in clearing virus
2012-09-06
Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London , discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.
This discovery by the team of scientists led by Professor Antonio Bertoletti, programme director and research director of the infection and immunity programme at SICS, could lead to ...
Mars's dramatic climate variations are driven by the Sun
2012-09-06
On Mars's poles there are ice caps of ice and dust with layers that reflect to past climate variations on Mars. Researchers from the Niels Bohr Institute have related the layers in the ice cap on Mars's north pole to variations in solar insolation on Mars, thus established the first dated climate history for Mars, where ice and dust accumulation has been driven by variations in insolation. The results are published in the scientific journal, Icarus.
The ice caps on Mars's poles are kilometres thick and composed of ice and dust. There are layers in the ice caps, which ...
A brain filter for clear information transmission
2012-09-06
This press release is available in German. Stefan Remy and colleagues at the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn have illuminated how this system works. "The system acts like a filter, only letting the most important impulses pass," explains Remy. "This produces the targeted neuronal patterns that are indispensible for long-term memory storage."
How does this refined control system work? How can inhibitory signals produce precise output signals? This was the question investigated by Remy and his colleagues. Scientists have known ...
Human genome far more active than thought
2012-09-06
The GENCODE Consortium expects the human genome has twice as many genes than previously thought, many of which might have a role in cellular control and could be important in human disease. This remarkable discovery comes from the GENCODE Consortium, which has done a painstaking and skilled review of available data on gene activity.
Among their discoveries, the team describe more than 10,000 novel genes, identify genes that have 'died' and others that are being resurrected. The GENCODE Consortium reference gene catalogue has been one of the underpinnings of the larger ...
Survival 'excellent' following living donor liver transplantation for acute liver failure
2012-09-06
Patients in Japan who underwent living donor liver transplantation (LDLT) for acute liver failure (ALF) were classified as having excellent outcomes, with ten-year survival at 73%. The findings, published in the September issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases (AASLD), suggest that the type of liver disease or treatment plan does not affect long-term patient survival following LDLT. Donor and patient age, however, does impact long-term outcome post-transplant.
According to the AASLD, roughly 2,000 Americans ...
Destroyed coastal habitats produce significant greenhouse gas
2012-09-06
DURHAM, N.C. -- Destruction of coastal habitats may release as much as 1 billion tons of carbon emissions into the atmosphere each year, 10 times higher than previously reported, according to a new Duke led study.
Published online this week in PLOS ONE, the analysis provides the most comprehensive estimate of global carbon emissions from the loss of these coastal habitats to date: 0.15 to 1.2 billion tons. It suggests there is a high value associated with keeping these coastal-marine ecosystems intact as the release of their stored carbon costs roughly $6-$42 billion ...
Storm of 'awakened' transposons may cause brain-cell pathologies in ALS, other illnesses
2012-09-06
Cold Spring Harbor, NY – A team of neuroscientists and informatics experts at Cold Spring Harbor Laboratory (CSHL) reports important progress in an effort to understand the relationship between transposons – sequences of DNA that can jump around within the genome, potentially causing great damage – and mechanisms involved in serious neurodegenerative disorders including ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), FTLD (frontotemporal lobar degeneration) and Alzheimer's disease.
A close analysis of previously unanalyzed genome data has led ...
Childhood sexual abuse linked to later heart attacks in men
2012-09-06
TORONTO, ON – Men who experienced childhood sexual abuse are three times more likely to have a heart attack than men who were not sexually abused as children, according to a new study from researchers at the University of Toronto. The researchers found no association between childhood sexual abuse and heart attacks among women.
In a paper published online this week in the journal Child Abuse & Neglect, investigators examined gender-specific differences in a representative sample of 5095 men and 7768 women aged 18 and over, drawn from the Center for Disease Control's 2010 ...
Promising new drug target for inflammatory lung diseases
2012-09-06
New Rochelle, NY, September 6, 2012—The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options. Therapies targeting IL-18 could prove effective against inflammatory diseases of the lung including bronchial asthma and chronic obstructive pulmonary disease (COPD), as described in a review article published in Journal of Interferon & Cytokine Research (http://www.liebertpub.com/jir), a peer-reviewed publication ...
Report: Strategies to prevent noise-induced hearing loss, tinnitus in soldiers
2012-09-06
DETROIT – Antioxidants, dietary supplements and high-tech brain imaging are among some of the novel strategies that may help detect, treat and even prevent noise-induced hearing loss and tinnitus among American troops, according to researchers at Henry Ford Hospital.
A culmination of nearly 25 years of research on noise-induced hearing loss – a growing medical issue that affects more than 12 percent of American troops returning from conflicts around the globe – will be presented Sept. 9 at the American Academy of Otolaryngology-Head & Neck Surgery annual meeting in Washington, ...